What is MET Inhibitor Drugs?
MET inhibitor drugs are the group of drugs that inhibits the mutated forms of the MET gene that may cause abnormal cell growth and spread in the body. These drugs are primarily used for the treatment of different types of cancers such as breast, colon, and lung cancers. According to World Health Organization (WHO), cancer is the second leading cause of death globally and is responsible for about 10 million deaths per year. The factors such as the Increased Prevalence of Cancers among People Worldwide and High Demand for Alternative Treatments for Cancers are the drivers for the global MET Inhibitor Drugs market. In addition, Increased Research and Development Funding also fueling the market growth. However, Limitations Associated with MET Inhibitor Drugs may hinder the market growth.
The market study is broken down by Type (C-Met Biological Inhibitors, Small Molecule C-Met Inhibitors, C-Met Antagonist Antibodies, HGF Antagonist Antibodies and Kringle Variant Antagonists) and major geographies with country level break-up.
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA estimates that Players from United States will contribute to the maximum growth of Global MET Inhibitor Drugs market throughout the predicted period.
Abbott Laboratories (United States), Johnson and Johnson (United States), Novartis International AG (Switzerland), Eli Lilly and Company (United States), Pfizer Inc. (United States), Merck & Co., Inc. (United States), Takeda Pharmaceutical Company (Japan), GlaxoSmithKline plc (United Kingdom), Amgen Inc. (United States), Bristol Myers Squibb (United States) and Daiichi Sankyo Company, Limited (Japan) are some of the key players that are part of study coverage.
AdvanceMarketAnalytics has segmented the market of Global MET Inhibitor Drugs market by Type, Application and Region.
On the basis of geography, the market of MET Inhibitor Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the MET Inhibitor Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-user, the sub-segment i.e. Hospitals will boost the MET Inhibitor Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
In May 2020, Novartis announced that the United States Food and Drug Administration (FDA) has approved Tabrecta (capmatinib, formerly INC280), an oral MET inhibitor for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA-approved test.
- Increased Research and Development Funding
- Increased Prevalence of Cancer among People Worldwide
- High Demand for Alternative Treatments for Cancers
- Growth in the Healthcare Infrastructure in Developing Countries
- Growth in the Healthcare Industry
- Huge Investments by Major Players
- Limitations Associated with MET Inhibitor Drugs
- Stringent Government Rules and Regulations
Key Target AudienceMET Inhibitor Drugs Manufacturers, Distributors, Emerging Companies, Research Professionals and End-users
About ApproachDuring this study the evaluation and validation of the market size is done through various sources including primary and secondary analysis. AMA Research & Media follows industrial and regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand companys positioning regarding market value, volume and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase